Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Phalanx Partnership

Voyageur Pharmaceuticals Ltd. has entered into a non-exclusive distribution agreement with Mexican pharmaceutical distributor PHALANX, Comercializadora e Importadora de Componentes SA DE CV, marking a significant expansion into Latin American healthcare markets. The agreement follows a non-binding Letter of Intent announced in June 2025 and establishes a strategic partnership focused on market expansion in Mexico's medical imaging sector.

Under the distribution framework, Phalanx will register Voyageur's barium contrast media products with Mexican health regulatory authorities and distribute them through its established network. Voyageur will provide support throughout the regulatory approval process, working collaboratively to advance market access and commercialization efforts. This partnership aligns both companies in a shared vision to establish Voyageur's market presence within Mexico's medical imaging and contrast media markets.

Phalanx brings substantial regional expertise to the partnership, operating as a leading pharmaceutical distributor with strong presence in Mexico and key Latin American markets that recognize Canadian regulatory approvals. The company provides comprehensive commercial intelligence and strategic market solutions for businesses entering the region, combining rigorous market analysis with operational execution to ensure successful product launches and sustainable growth. More information about Phalanx's services can be found at https://voyageurpharmaceuticals.ca.

This agreement represents a key milestone in Voyageur's international growth strategy, expanding the company's global footprint and supporting access to underserved markets with increasing demand for high-quality contrast media. Brent Willis, CEO of Voyageur, stated that the agreement reflects the company's continued commitment to expanding global access to innovative, cost-effective imaging solutions, noting that Latin America represents a critical market in their expansion plan that lays groundwork for long-term growth.

The partnership's importance extends beyond immediate market entry, addressing broader healthcare accessibility issues in the region. By introducing cost-effective contrast media solutions through established distribution channels, the collaboration could potentially improve medical imaging capabilities in Mexican healthcare facilities. Sales of Voyageur's barium sulfate contrast media products in Mexico and other Latin American countries will be subject to local regulatory approval processes, with Phalanx taking the lead in preparing and submitting necessary filings supported by Voyageur's technical and regulatory team.

This expansion comes as Voyageur continues developing barium and iodine Active Pharmaceutical Ingredients that offer high-performance imaging contrast agents. The company's strategic focus on vertical integration in the barium and iodine contrast markets positions it to potentially become a significant player in global radiology drug manufacturing. The Frances Creek Project, which Voyageur owns 100%, contains mineral resources the company believes can replace current synthetic pharmaceutical barium sulfate products with higher quality imaging alternatives.